Supplementary Table S4 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry

Supplementary Table S4 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry

<p>Differentially expressed genes by race</p>

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Nadia Mezghani (15055724) (author)
Weitere Verfasser:	Alexandria Yao (15055727) (author), Daria Vasilyeva (15055730) (author), Nicole Kaplan (15055733) (author), Austin Shackelford (15055736) (author), Angela Yoon (15055739) (author), Elizabeth Phillipone (15055742) (author), Sunil Dubey (15055745) (author), Gary K. Schwartz (15054959) (author), Alison M. Taylor (15055748) (author), Fatemeh Momen-Heravi (10160853) (author)
Veröffentlicht:	2025
Schlagworte:	Cancer Therapeutic Research and Development Clinical Research and Trials Head, Neck & Oral Cancers Precision Medicine Translational Research
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Supplementary Table S1 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
von: Nadia Mezghani (15055724)
Veröffentlicht: (2025)

Supplementary Table S3 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
von: Nadia Mezghani (15055724)
Veröffentlicht: (2025)

Figure 1 from <i>In Situ</i> Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
von: Richard C. Gregory (15132698)
Veröffentlicht: (2025)

Figure 2 from <i>In Situ</i> Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
von: Richard C. Gregory (15132698)
Veröffentlicht: (2025)

Figure 3 from <i>In Situ</i> Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
von: Richard C. Gregory (15132698)
Veröffentlicht: (2025)

Figure 4 from <i>In Situ</i> Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
von: Richard C. Gregory (15132698)
Veröffentlicht: (2025)

Figure 5 from <i>In Situ</i> Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
von: Richard C. Gregory (15132698)
Veröffentlicht: (2025)

Table 1 from <i>In Situ</i> Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
von: Richard C. Gregory (15132698)
Veröffentlicht: (2025)

Table 2 from <i>In Situ</i> Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
von: Richard C. Gregory (15132698)
Veröffentlicht: (2025)

Tables 2 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
von: Simon P. Beyaert (17141915)
Veröffentlicht: (2025)

Tables 3 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
von: Simon P. Beyaert (17141915)
Veröffentlicht: (2025)

Supplementary Figure from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer
von: Sankar Jagadeeshan (15112900)
Veröffentlicht: (2025)

Supplementary Figures 1 from Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors
von: Luana Guimaraes Sousa (16534377)
Veröffentlicht: (2025)

Supplement 4 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
von: Fei Cao (22247259)
Veröffentlicht: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
von: Michelle L. Mierzwa (14963463)
Veröffentlicht: (2025)

Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
von: Bouchra Tawk (15389486)
Veröffentlicht: (2025)

Supplementary Figure S1 from Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
von: Glenn J. Hanna (15036909)
Veröffentlicht: (2025)

Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Figure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Figure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Table 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Supplementary Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Supplementary Figure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Supplementary Figure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Supplementary Figure 4 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
von: Michelle Echevarria (21759856)
Veröffentlicht: (2025)

Figure S1 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S10 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S11 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S12 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S13 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S14 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S15 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S16 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S17 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S18 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S2 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S3 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S4 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S5 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)

Figure S6 from Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
von: Keiichi Koshizuka (17078773)
Veröffentlicht: (2025)